Concepedia

The effectiveness and value of lecanemab for early Alzheimer disease: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum

Abigail C. Wright, Grace A. Lin, Melanie D. Whittington, Foluso Agboola, Serina Herron-Smith, David M. Rind, Steven D. Pearson

Journal of Managed Care & Specialty Pharmacy · 2023 · 36 citations · 12 references

DOIFull text

Open access

Concepts

Abstract

The pivotal trial of lecanemab was CLARITY AD, a phase III, randomized control trial that evaluated the efficacy of 10mg/kg of intravenous lecanemab administered every

References

12

Lecanemab in Early Alzheimer’s Disease

Christopher H. van Dyck, Chad J. Swanson, Paul Aisen et al. · New England Journal of Medicine · 2022 · 5.2K citations · Full text

, , +17

Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity

Steven T. DeKosky, Stephen W. Scheff · Annals of Neurology · 1990 · 2.4K citations

, , +17

2022 Alzheimer's disease facts and figures

Alzheimer s & Dementia · 2022 · 2.4K citations

, , +17

Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium

Lindsay A. Farrer · JAMA · 1997 · 1.9K citations

, , +17

Inequalities in dementia incidence between six racial and ethnic groups over 14 years

Elizabeth Rose Mayeda, M. Maria Glymour, Charles P. Quesenberry et al. · Alzheimer s & Dementia · 2016 · 862 citations

, , +17